Clinical trial
First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment
NCT04037397 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment
- Lead sponsor
- University of Pennsylvania
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 24, 2019
- Completion date
- October 1, 2024
- Enrollment
- 25 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.